The agency first approved Sutent in 2006 to treat patients with gastrointestinal stromal tumors and advanced kidney cancer. The drug has also been approved to treat a certain form of pancreatic cancer.
Under the latest approval, Sutent may now be used to treat patients who’ve had a kidney surgically removed to lower the risk of cancer recurrence. Sutent is the first drug approved for this indication.
More articles on supply chain:
Geisinger, Intermountain among 11 healthcare groups urging CMS to add device identifiers to claims form
Genentech earns FDA approval for hemophilia drug
6 must-reads for supply chain leaders this week
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.